Roche (RHHBY)'s Avastin Boosts Survival in Advanced Ovarian Cancer
10/22/2013 7:44:52 AM
A new UK-based trial of Roche's Avastin demonstrates that it improves overall survival (OS) in women with high-risk advanced ovarian cancer, bringing new hope to patients despite the drug not being routinely available on the National Health Service. Data out this morning show that women at highest risk of their cancer recurring given Avastin in combination with chemotherapy, and then continued maintenance Avastin, lived on average 9.4 months longer than those on chemotherapy alone (median OS 39.7 months vs. 30.3 months).
Help employers find you! Check out all the jobs and post your resume.
comments powered by